Given Imaging Announces New Studies That Affirm Pillcam Sb As The Gold Standard For Detecting And Di

When Should I Perform a Push Enteroscopy, and Are Overtube and Fluoroscopy Necessary for the Procedure?

Given Imaging is committed to delivering breakthrough innovations to the GI community and supporting its ongoing clinical needs. Given Imaging's headquarters are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia, Vietnam, Hong Kong and Brazil. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Such forward-looking statements include statements relating to the Company exploring strategic alternatives and considering possible strategic transactions involving the Company. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to successfully complete any necessary or required clinical studies with our products, (3) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (4) our success in implementing our sales, marketing and manufacturing plans, (5) the level of adoption of our products by medical practitioners, (6) the emergence of other products that may make our products obsolete, (7) lack of an appropriate bowel preparation materials to be used with our PillCam COLON capsule, (8) protection and validity of patents and other intellectual property rights, (9) the impact of currency exchange rates, (10) the effect of competition by other companies, (11) the outcome of significant litigation, (12) our ability to obtain reimbursement for our product from government and commercial payors, (13) quarterly variations in operating results, (14) the possibility of armed conflict or civil or military unrest in Israel, (15) the impact of global economic conditions, (16) our ability to successfully integrate acquired businesses, (17) changes and reforms in applicable healthcare laws and regulations, (18) quality issues and adverse events related to our products, such as capsule retention, aspiration and failure to attach or detach, bleeding or perforation that could require us to recall products and impact our sales and net income, and (19) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except to the extent expressly required under applicable law, the Company undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. how much is yours worth

Small Bowel Perforation

Bacteria from within the intestines can cause "peritonitis", or inflammation within the abdominal cavity. The patient can develop sepsis and possibly die. Thus, small bowel perforation must be corrected quickly. Causes of Small Bowel Perforation Perforation from a duodenal ulcer, prior to the 1980s, was the most common cause of small bowel perforation. Today, perforation that occurs during endoscopy is the most common cause, specifically during a procedure called ERCP with endoscopic sphincterotomy. ERCP (endoscopic retrograde cholangiopancreatography) is a procedure that allows physicians to evaluate disorders of the ducts from the liver and pancreas that carry bile and other substances. (Endoscopy is the use of a video camera at the end of a long, thin tube to look at the inside of the esophagus, stomach, duodenum, or other orifice.) Other causes of perforation include infections (tuberculosis and cytomegalovirus), Crohns disease, ischemia, injury from radiation therapy, cancer (lymphoma, adenocarcinoma, etc.), and swallowed foreign bodies. Symptoms of Small Bowel Perforation Symptoms include abdominal pain, tenderness to palpation, distension, fever, and tachycardia. Symptoms can occur much more gradually with duodenal perforation, since most of the duodenum is retroperitoneal, and the intestinal contents, therefore, would not leak into the peritoneal cavity. Diagnosis of Small Bowel Perforation The best diagnostic tests are an upper GI study with water-soluble contrast (Gastrografin) or a CT scan. Free air in the peritoneal cavity and contrast extravasation may be seen. Abdominal X-ray may also show air underneath the diaphragm (air that has leaked from within the intestines, through the perforation, and into the peritoneal cavity). Treatment of Small Bowel Perforation Small intestinal perforations that leak into the peritoneal cavity require surgery. The perforated segment may be closed primarily with sutures or the segment may be resected. If the patient is unstable or if florid peritonitis is present, it may be best to create an ostomy (allowing the intestinal contents to empty into a bag attached to the skin) for several weeks while the intestines are healing. A duodenal perforation that is retroperitoneal may not need surgery. bonuses

In summary, push enteroscopy continues to be a mainstay in the evaluation and therapy of small intestinal disease and in the postoperative anatomy. It is a technique with a practical value that can be forgotten in the shadow of balloon enteroscopy enthusiasm. Fluoroscopy offers little if any benefit, except when push enteroscopy is performed for ERCP in the postoperative anatomy of a Roux-en-Y or a Bill Roth II or in the placement of an enteral SEMS. References 1. Harewood G, Gostout CJ, Farrell MA, Knipschield MA. Prospective controlled assessment of variable stiffness enteroscopy. Gastrointest Endosc. 2003;58(2):267-271. 2. Gostout CJ, Bender CE. Cholangiopancreatography, sphincterotomy, and common duct stone removal via Roux-en-Y limb enteroscopy. Gastroenterology. 1988;95(1):156-163. 3. Singh P, Amitabh C. Push-type enteroscopy in occult gastrointestinal bleeding. blog site{44abbb1a-e46b-449e-bbaf-44965a4dd5e7}/when-should-i-perform-a-